<DOC>
	<DOCNO>NCT02258321</DOCNO>
	<brief_summary>This study compare blood level PPI-668 result two different formulation - current capsule new tablet , T003 .</brief_summary>
	<brief_title>Phase 1 Study Relative Bioavailability PPI-668 New Tablet Versus Capsule Formulations</brief_title>
	<detailed_description />
	<criteria>Have ability understand sign write informed consent form nonsmoker body mass index ( BMI ) 18.0 29.9 kg/m2 ( inclusive ) HIV1 antibody negative . hepatitis B ( HBV ) surface antigen negative . hepatitis C ( HCV ) antibody negative . Pregnant lactating subject . Have serious active medical psychiatric illness , opinion Investigator , would interfere subject treatment , assessment , compliance protocol . This would include renal , cardiac , hematologic , hepatic , pulmonary ( include chronic asthma ) , endocrine ( e.g. , diabetes ) , central peripheral nervous , gastrointestinal ( include ulcer ) , vascular , metabolic ( thyroid disorder , adrenal disease ) , immunodeficiency disorder , active infection , malignancy clinically significant require treatment . Have participate investigational trial involve administration investigational compound within 30 day prior study dose . Current alcohol substance abuse judge Investigator potentially interfere subject compliance . Have poor venous access unable donate blood . Have donate blood within 56 day study dose . Have donate plasma within 7 day study dose . Have take prescription medication overthecounter medication include herbal product within 28 day commence study drug dose exception vitamin and/or acetaminophen and/or ibuprofen and/or contraceptive medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>